Phosphorylation of RSK2 at Tyr529 by FGFR2-p38 enhances human mammary epithelial cells migration

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 11, 2014, Pages 2461-2470

  Czaplinska, Dominika ^a   Turczyk, Lukasz ^a   Grudowska, Alicja ^a   Mieszkowska, Magdalena ^a   Lipinska, Andrea D ^a   Skladanowski, Andrzej C ^a   Zaczek, Anna J ^a   Romanska, Hanna M ^b   Sadej, Rafal ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Breast cancer; FGF2; FGFR2; Migration; Ribosomal S6 kinase; RSK2

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACTIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; RIBOSOMAL S6 KINASE 2; S6 KINASE; SERINE; THREONINE; U 120; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST EPITHELIUM; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FOCAL ADHESION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84905230198     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.06.022     Document Type: Article

References (59)

1. Romeo Y., Zhang X., Roux P.P. Regulation and function of the RSK family of protein kinases. Biochem. J. 2012, 441:553-569.
2. Jones S.W., Erikson E., Blenis J., Maller J.L., Erikson R.L. A Xenopus ribosomal protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:3377-3381.
3. Fisher T.L., Blenis J. Evidence for two catalytically active kinase domains in pp90rsk. Mol. Cell. Biol. 1996, 16:1212-1219.
4. Bjørbaek C., Zhao Y., Moller D.E. Divergent functional roles for p90rsk kinase domains. J. Biol. Chem. 1995, 270:18848-18852.
5. Vik T.A., Ryder J.W. Identification of serine 380 as the major site of autophosphorylation of Xenopus pp90rsk. Biochem. Biophys. Res. Commun. 1997, 235:398-402.
6. Sulzmaier F.J., Ramos J.W. RSK isoforms in cancer cell invasion and metastasis. Cancer Res. 2013, 73:6099-6105.
7. Cuadrado A., Nebreda A.R. New insights into RSK activation and hematopoietic cancer. Cancer Cell 2007, 12:187-189.
8. Clark D.E., Errington T.M., Smith J.A., Frierson H.F., Weber M.J., Lannigan D.A. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res. 2005, 65:3108-3116.
9. Smith J.A., Poteet-Smith C.E., Xu Y., Errington T.M., Hecht S.M., Lannigan D.A. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 2005, 65:1027-1034.
10. Stratford A.L., Reipas K., Hu K., Fotovati A., Brough R., Frankum J., Takhar M., Watson P., Ashworth A., Lord C.J., Lasham A., Print C.G., Dunn S.E. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells 2012, 30:1338-1348.
11. Kang S., Elf S., Lythgoe K., Hitosugi T., Taunton J., Zhou W., Xiong L., Wang D., Muller S., Fan S., Sun S.Y., Marcus A.I., Gu T.L., Polakiewicz R.D., Chen Z.G., Khuri F.R., Shin D.M., Chen J. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J. Clin. Invest. 2010, 120:1165-1177.
12. Lara R., Mauri F.A., Taylor H., Derua R., Shia A., Gray C., Nicols A., Shiner R.J., Schofield E., Bates P.A., Waelkens E., Dallman M., Lamb J., Zicha D., Downward J., Seckl M.J., Pardo O.E. An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis. Oncogene 2011, 30:3513-3521.
13. Larrea M.D., Hong F., Wander S.A., da Silva T.G., Helfman D., Lannigan D., Smith J.A., Slingerland J.M. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:9268-9273.
14. Sassone-Corsi P., Mizzen C.A., Cheung P., Crosio C., Monaco L., Jacquot S., Hanauer A., Allis C.D. Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Science 1999, 285:886-891.
15. De Cesare D., Jacquot S., Hanauer A., Sassone-Corsi P. Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:12202-12207.
16. Lazar D.F., Wiese R.J., Brady M.J., Mastick C.C., Waters S.B., Yamauchi K., Pessin J.E., Cuatrecasas P., Saltiel A.R. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J. Biol. Chem. 1995, 270:20801-20807.
17. Law J.H., Habibi G., Hu K., Masoudi H., Wang M.Y., Stratford A.L., Park E., Gee J.M., Finlay P., Jones H.E., Nicholson R.I., Carboni J., Gottardis M., Pollak M., Dunn S.E. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008, 68:10238-10246.
18. Anjum R., Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol. 2008, 9:747-758.
19. Stratford A.L., Fry C.J., Desilets C., Davies A.H., Cho Y.Y., Li Y., Dong Z., Berquin I.M., Roux P.P., Dunn S.E. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 2008, 10:R99.
20. Chen R.H., Abate C., Blenis J. Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10952-10956.
21. Cho Y.Y., He Z., Zhang Y., Choi H.S., Zhu F., Choi B.Y., Kang B.S., Ma W.Y., Bode A.M., Dong Z. The p53 protein is a novel substrate of ribosomal S6 kinase 2 and a critical intermediary for ribosomal S6 kinase 2 and histone H3 interaction. Cancer Res. 2005, 65:3596-3603.
22. Doehn U., Hauge C., Frank S.R., Jensen C.J., Duda K., Nielsen J.V., Cohen M.S., Johansen J.V., Winther B.R., Lund L.R., Winther O., Taunton J., Hansen S.H., Frödin M. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol. Cell 2009, 35:511-522.
23. Kang S., Dong S., Gu T.L., Guo A., Cohen M.S., Lonial S., Khoury H.J., Fabbro D., Gilliland D.G., Bergsagel P.L., Taunton J., Polakiewicz R.D., Chen J. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 2007, 12:201-214.
24. Pan Z.Z., Devaux Y., Ray P. Ribosomal S6 kinase as a mediator of keratinocyte growth factor-induced activation of Akt in epithelial cells. Mol. Biol. Cell 2004, 15:3106-3113.
25. Hunter D.J., Kraft P., Jacobs K.B., Cox D.G., Yeager M., Hankinson S.E., Wacholder S., Wang Z., Welch R., Hutchinson A., Wang J., Yu K., Chatterjee N., Orr N., Willett W.C., Colditz G.A., Ziegler R.G., Berg C.D., Buys S.S., McCarty C.A., Feigelson H.S., Calle E.E., Thun M.J., Hayes R.B., Tucker M., Gerhard D.S., Fraumeni J.F., Hoover R.N., Thomas G., Chanock S.J. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 2007, 39:870-874.
26. Cerliani J.P., Guillardoy T., Giulianelli S., Vaque J.P., Gutkind J.S., Vanzulli S.I., Martins R., Zeitlin E., Lamb C.A., Lanari C. Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res. 2011, 71:3720-3731.
27. Kim S., Dubrovska A., Salamone R.J., Walker J.R., Grandinetti K.B., Bonamy G.M., Orth A.P., Elliott J., Porta D.G., Garcia-Echeverria C., Reddy V.A. FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells. PLoS One 2013, 8:e51671.
28. Okada-Ban M., Thiery J.P., Jouanneau J. Fibroblast growth factor-2. Int. J. Biochem. Cell Biol. 2000, 32:263-267.
29. Bikfalvi A., Klein S., Pintucci G., Rifkin D.B. Biological roles of fibroblast growth factor-2. Endocr. Rev. 1997, 18:26-45.
30. Cao X.C., Zhang W.R., Cao W.F., Liu B.W., Zhang F., Zhao H.M., Meng R., Zhang L., Niu R.F., Hao X.S., Zhang B. Aquaporin3 is required for FGF-2-induced migration of human breast cancers. PLoS One 2013, 8:e56735.
31. Khurana A., Liu P., Mellone P., Lorenzon L., Vincenzi B., Datta K., Yang B., Linhardt R.J., Lingle W., Chien J., Baldi A., Shridhar V. HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res. 2011, 71:2152-2161.
32. Liu J.F., Crépin M., Liu J.M., Barritault D., Ledoux D. FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem. Biophys. Res. Commun. 2002, 293:1174-1182.
33. Sharpe R., Pearson A., Herrera-Abreu M.T., Johnson D., Mackay A., Welti J.C., Natrajan R., Reynolds A.R., Reis-Filho J.S., Ashworth A., Turner N.C. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin. Cancer Res. 2011, 17:5275-5286.
34. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., Harris A.L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997, 57:963-969.
35. Liu Y., Wang J.L., Chang H., Barsky S.H., Nguyen M. Breast-cancer diagnosis with nipple fluid bFGF. Lancet 2000, 356:567.
36. Giri D., Ropiquet F., Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin. Cancer Res. 1999, 5:1063-1071.
37. Baldwin G., Novitskaya V., Sadej R., Pochec E., Litynska A., Hartmann C., Williams J., Ashman L., Eble J.A., Berditchevski F. Tetraspanin CD151 regulates glycosylation of (alpha)3(beta)1 integrin. J. Biol. Chem. 2008, 283:35445-35454.
38. Gartside M.G., Chen H., Ibrahimi O.A., Byron S.A., Curtis A.V., Wellens C.L., Bengston A., Yudt L.M., Eliseenkova A.V., Ma J., Curtin J.A., Hyder P., Harper U.L., Riedesel E., Mann G.J., Trent J.M., Bastian B.C., Meltzer P.S., Mohammadi M., Pollock P.M. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol. Cancer Res. 2009, 7:41-54.
39. Bryant M.R., Marta C.B., Kim F.S., Bansal R. Phosphorylation and lipid raft association of fibroblast growth factor receptor-2 in oligodendrocytes. Glia 2009, 57:935-946.
40. Tarkkonen K.M., Nilsson E.M., Kähkönen T.E., Dey J.H., Heikkilä J.E., Tuomela J.M., Liu Q., Hynes N.E., Härkönen P.L. Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PLoS One 2012, 7:e49970.
41. Guo M., Liu W., Serra S., Asa S.L., Ezzat S. FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. Cancer Res. 2012, 72:2017-2027.
42. Kunii K., Davis L., Gorenstein J., Hatch H., Yashiro M., Di Bacco A., Elbi C., Lutterbach B. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008, 68:2340-2348.
43. Ornitz D.M. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000, 22:108-112.
44. Wesche J., Haglund K., Haugsten E.M. Fibroblast growth factors and their receptors in cancer. Biochem. J. 2011, 437:199-213.
45. Mohammadi M., Dikic I., Sorokin A., Burgess W.H., Jaye M., Schlessinger J. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol. Cell. Biol. 1996, 16:977-989.
46. Bansal R., Magge S., Winkler S. Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells. J. Neurosci. Res. 2003, 74:486-493.
47. Pardo O.E., Latigo J., Jeffery R.E., Nye E., Poulsom R., Spencer-Dene B., Lemoine N.R., Stamp G.W., Aboagye E.O., Seckl M.J. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res. 2009, 69:8645-8651.
48. Richards S.A., Fu J., Romanelli A., Shimamura A., Blenis J. Ribosomal S6 kinase 1 (RSK1) activation requires signals dependent on and independent of the MAP kinase ERK. Curr. Biol. 1999, 9:810-820.
49. Smith J.A., Poteet-Smith C.E., Malarkey K., Sturgill T.W. Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo. J. Biol. Chem. 1999, 274:2893-2898.
50. Kang S., Dong S., Guo A., Ruan H., Lonial S., Khoury H.J., Gu T.L., Chen J. Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529. J. Biol. Chem. 2008, 283:4652-4657.
51. Zaru R., Ronkina N., Gaestel M., Arthur J.S., Watts C. The MAPK-activated kinase Rsk controls an acute Toll-like receptor signaling response in dendritic cells and is activated through two distinct pathways. Nat. Immunol. 2007, 8:1227-1235.
52. Jin L., Li D., Lee J.S., Elf S., Alesi G.N., Fan J., Kang H.B., Wang D., Fu H., Taunton J., Boggon T.J., Tucker M., Gu T.L., Chen Z.G., Shin D.M., Khuri F.R., Kang S. p90 RSK2 mediates antianoikis signals by both transcription-dependent and -independent mechanisms. Mol. Cell. Biol. 2013, 33:2574-2585.
53. Gawecka J.E., Young-Robbins S.S., Sulzmaier F.J., Caliva M.J., Heikkilä M.M., Matter M.L., Ramos J.W. RSK2 protein suppresses integrin activation and fibronectin matrix assembly and promotes cell migration. J. Biol. Chem. 2012, 287:43424-43437.
54. Woo M.S., Ohta Y., Rabinovitz I., Stossel T.P., Blenis J. Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol. Cell. Biol. 2004, 24:3025-3035.
55. Loo D.T., Kanner S.B., Aruffo A. Filamin binds to the cytoplasmic domain of the beta1-integrin. Identification of amino acids responsible for this interaction. J. Biol. Chem. 1998, 273:23304-23312.
56. Kostenko S., Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell. Mol. Life Sci. 2009, 66:3289-3307.
57. Vial D., McKeown-Longo P.J. Epidermal growth factor (EGF) regulates α5β1 integrin activation state in human cancer cell lines through the p90RSK-dependent phosphorylation of filamin A. J. Biol. Chem. 2012, 287:40371-40380.
58. Smolen G.A., Zhang J., Zubrowski M.J., Edelman E.J., Luo B., Yu M., Ng L.W., Scherber C.M., Schott B.J., Ramaswamy S., Irimia D., Root D.E., Haber D.A. A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. Genes Dev. 2010, 24:2654-2665.
59. Li D., Jin L., Alesi G.N., Kim Y.M., Fan J., Seo J.H., Wang D., Tucker M., Gu T.L., Lee B.H., Taunton J., Magliocca K.R., Chen Z.G., Shin D.M., Khuri F.R., Kang S. The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. J. Biol. Chem. 2013, 288:32528-32538.